BRAF and melanoma: Although we demonstrated the less cytotoxic effects to ArcA on melanoma with wild-type BRAF using B16F10 cell lines, there are limitations related to species differences, which complicate the interpretation of sensitivity variations by ArcA based on BRAF mutation status.